Contrasting VanEck Biotech ETF (NASDAQ:BBH) & BlackRock MuniYield New York Quality Fund (NYSE:MYN)

VanEck Biotech ETF (NASDAQ:BBHGet Free Report) and BlackRock MuniYield New York Quality Fund (NYSE:MYNGet Free Report) are both small-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a breakdown of recent ratings and target prices for VanEck Biotech ETF and BlackRock MuniYield New York Quality Fund, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VanEck Biotech ETF 0 4 2 0 2.65
BlackRock MuniYield New York Quality Fund 0 0 0 0 0.00

VanEck Biotech ETF currently has a consensus price target of $160.75, suggesting a potential upside of 0.00%. Given VanEck Biotech ETF’s stronger consensus rating and higher probable upside, analysts clearly believe VanEck Biotech ETF is more favorable than BlackRock MuniYield New York Quality Fund.

Institutional & Insider Ownership

32.0% of VanEck Biotech ETF shares are owned by institutional investors. Comparatively, 29.3% of BlackRock MuniYield New York Quality Fund shares are owned by institutional investors. 1.0% of BlackRock MuniYield New York Quality Fund shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares VanEck Biotech ETF and BlackRock MuniYield New York Quality Fund”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VanEck Biotech ETF N/A N/A N/A N/A N/A
BlackRock MuniYield New York Quality Fund $19.20 million 20.29 N/A N/A N/A

Profitability

This table compares VanEck Biotech ETF and BlackRock MuniYield New York Quality Fund’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VanEck Biotech ETF N/A N/A N/A
BlackRock MuniYield New York Quality Fund N/A N/A N/A

Dividends

VanEck Biotech ETF pays an annual dividend of $1.25 per share and has a dividend yield of 0.8%. BlackRock MuniYield New York Quality Fund pays an annual dividend of $0.54 per share and has a dividend yield of 5.3%.

Volatility and Risk

VanEck Biotech ETF has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, BlackRock MuniYield New York Quality Fund has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Summary

VanEck Biotech ETF beats BlackRock MuniYield New York Quality Fund on 5 of the 8 factors compared between the two stocks.

About VanEck Biotech ETF

(Get Free Report)

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.

About BlackRock MuniYield New York Quality Fund

(Get Free Report)

BlackRock MuniYield New York Quality Fund, Inc. is a closed ended fixed income mutual fund launched by BlackRock, Inc. It is managed by BlackRock Advisors, LLC. The fund invests in fixed income markets. It invests primarily in a portfolio of long-term investment grade municipal bonds exempt from federal income taxes and New York State and New York City personal income taxes. BlackRock MuniYield New York Quality Fund, Inc was formed on March 16, 1992 and is domiciled in United States.

Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.